However, in cHL, although the initial responsiveness to PD-1 blockade was remarkably high, during long-term follow-up, relapse of disease was emerged, and ongoing responses were only sustained in less than one-third of all responders (Armand et al., 2018; Chen et al., 2019). The gene discussed is PDCD1; the disease is classic Hodgkin lymphoma.